The digital pathology market was valued at USD 1.5 billion in 2025 and is estimated at USD 1.6 billion in 2026. Grand View Research projects it will reach USD 3.0 billion by 2033, growing at a CAGR of 8.6% from 2026 to 2033. North America led with a 39.92% revenue share in 2025, and Asia Pacific is expected to be the fastest-growing region.

Market Overview & Key Segments

How big is the digital pathology market?

Digital pathology turns glass slides into high-resolution digital images that pathologists can view, share and analyze with software, including AI. Taking the USD 1.5 billion (2025) and USD 3.0 billion (2033) endpoints, the digital pathology market is set to roughly double in eight years. That points to steady, infrastructure-led growth rather than a short hype cycle. The report is segmented by product, type, application, therapeutic area, end use and region.

Which segments lead the market?

Software is the biggest product category, with a 42.88% revenue share in 2025. The device category, which covers scanners and slide management systems, sits alongside it, and storage systems form a third product group. By type, human pathology holds the largest share.

Oncology is the dominant therapeutic area at 52.02%, which fits the global cancer burden. The National Cancer Institute figures cited in the report show almost 20 million new cancer cases and 9.7 million cancer-related deaths in 2022. By application, academic research leads with 45.76%. Among end users, hospitals hold the top position with 37.15%.

The figures in this article draw on Grand View Research’s market analysis. Continue your research with their Prism AI tool for more data and insights.

Where the growth is heading

The segments that lead today are not the ones the report flags as fastest-growing, and this gap is the most useful insight in the data:

• Device is the fastest-growing product, as scanner adoption widens.
• Veterinary is the fastest-growing type.
• Cardiovascular is the fastest-growing therapeutic area.
• Disease diagnosis is the fastest-growing application.
• Diagnostic labs are the fastest-growing end user.

Read together, today’s revenue sits in research-heavy, oncology-focused, hospital-based use. Future momentum is moving toward routine clinical diagnosis, commercial laboratories and new disease areas. Vendors that only serve academic research buyers may find their addressable market shifting under them.

Download a free sample report or claim your copy of this full market intelligence report

Regional picture

North America’s 39.92% share rests on government initiatives, sustained R&D investment, rising digital imaging adoption and the presence of major vendors. The U.S. is the largest national market in the region, supported by high per-capita healthcare spending and growing approvals of AI tools for conditions such as invasive breast cancer and skin lesions.

Europe is expected to grow at a significant CAGR. The European Institute of Biomedical Imaging Research has invested more than USD 66.84 million in biomedical imaging over the past decade. In Germany, the Digital Pathology Commission of the Federal Association of German Pathologists has issued guidelines for digital diagnostics and virtual microscopy.

Asia Pacific is the growth engine, driven by rapid digitalization and rising cancer prevalence. An example is the June 2023 partnership between Aignostics and Virchow Laboratories to bring AI pathology into Chinese clinical and research work.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

Key Drivers & Trends

Rising cancer prevalence and the need for speed

The main driver of the digital pathology market is chronic disease, especially cancer. Pathologists need data that helps tailor therapy, and digital workflows speed up diagnosis, improve accuracy and support therapeutic recommendations. Growing demand for faster diagnostic tools and for better workflow efficiency reinforces this.

AI is automating the slide review

AI is changing how images are analyzed. Pathologists once marked regions of interest in tissue samples by hand, and AI now automates that step. This reduces manual effort and the risk of human error. Falling hardware costs, the growing role of big data in healthcare and rising venture capital investment are also pulling AI-enabled pathology forward. A 2024 study in Breast Cancer Research showed deep learning models such as ResNet50, Transformer and Hover-net being applied to image enhancement, segmentation and classification in breast cancer diagnosis.

Integrated workflows and partnerships

Healthcare providers want records that can be accessed across facilities, so vendors are launching integrated solutions through partnerships. In February 2025, Charles River Laboratories and Deciphex expanded their partnership to offer integrated image management, distribution and archiving, with AI tools built for toxicologic pathology. Similar moves include Hamamatsu’s multi-year distribution deal with Siemens Healthineers (March 2023) and Owkin’s integration of its colorectal cancer AI diagnostic with Sectra (November 2023).

Drug discovery and precision medicine

Pharma and biotech companies are using digital pathology for translational research, biomarker analysis and companion diagnostics. Research commissioned by Proscia in 2023 found that nearly 75% of surveyed life sciences organizations had invested in digital pathology to strengthen R&D. As precision oncology expands, pathology imaging combined with genomics and spatial biology becomes more valuable.

Veterinary pathology as an early adopter

Veterinary pathologists are adopting AI platforms for preclinical drug development, and rules around virtual slides in veterinary diagnosis are less restrictive. In April 2024, SpecialtyVETPATH selected Proscia’s Concentriq platform to move to a fully digital workflow.

Competition, regulation and implementation

The industry is slightly fragmented, with many providers entering. Innovation, partnership activity and regulatory impact are all rated high. Mergers and acquisitions are moderate, as seen in Fujifilm’s February 2023 purchase of Inspirata’s digital pathology business. Compliance with FDA rules, HIPAA and CLIA shapes product design and go-to-market timelines.

Product innovation continues. Indica Labs released HALO 4.0 in May 2024, and Leica Biosystems upgraded its Aperio GT 450 scanner in January 2025 with DICOM-compatible files and AI-based artifact detection.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Adoption is as much about change management as technology. Portugal’s IMP Diagnostics moved in phases, starting with barcode tracking and partial digitization and adding training, and reported faster turnaround times and better remote collaboration.

Outlook

The digital pathology market is moving from a research tool to routine diagnostic infrastructure. Over 2026 to 2033, the fastest gains are expected in scanners, diagnostic labs, cardiovascular applications and Asia Pacific. These sit on top of an oncology-led, software-heavy base.

Check Out Our Dedicated Business Offerings –

• Healthcare Facility Mapping & Intelligence Platform: Map and analyze U.S. healthcare facilities. Explore now